About Ophthalmic Reconstructive Surgery
Reconstructive surgery of the eye takes place following irreparable damage to the eye’s integrity. Such damage can result following trauma, iatrogenic damage (damage caused unintentionally during a previous surgical procedure) or as a result of an inflammatory/connective tissue disease process. In these instances, the tissue can incur such damage that direct and immediate closure becomes impossible making patching the area with preserved and processed tissue the only treatment option.
CorNeat EverPatch Advantages
Inert and non-degradable material –
Bio-mechanical integration coupled with a minor and progressively subsiding, inflammatory response
Extremely easy to handle and suture
Elastic and durable (cannot be torn by the sutures)
Synthetic and therefore cannot carry or transmit disease
Reduces operating time and eye bank costs
Eliminates complexities related to the transportation and storage of biological materials
Readily available, off-the-shelf, device
Translucent when wet
Hardly visible when implanted
The CorNeat EverPatch (scleral patch) is the first inert, synthetic and non-degradable tissue substitute for use in ophthalmic surgeries. The CorNeat EverPatch replaces the use of human tissue and degradable collagen patches for covering and concealing implants such as glaucoma drainage devices and sealing the eye in cases of missing tissue.
The CorNeat EverPatch is composed of a non-woven, polymer matrix, which imitates the extracellular matrix, stimulating cellular colonization and integration with the surrounding tissue.
Covering irritating implants such as in glaucoma tube shunts or exposed sutures, displacing the need for preserved tissue/collagen.
Covering tissue gaps/weaknesses, resulting either from traumatic, disease related or iatrogenic damage.
Clinical trials for the CorNeat EverPatch are planned to begin in the second half of 2020, with sites planned in Canada, France and Kenya. The trials are geared toward obtaining a CE marking during 2021. CorNeat Vision plans to extend the solution to the US market as a second step and work toward FDA approval. The exact FDA path will be coordinated with authorities in the second half of 2020.
The plans above are subject to regulatory approvals and requirements.
For more information: clinicaltrials.gov